Glempa L 25/5mg Tablet 10's
Rs. 194.07
Title
Glempa L 25/5mg Tablet 10's
Prescription drug
About: Glempa L 25/5 is a dual‑agent antidiabetic for type 2 diabetes in adults.
Usage Instructions: Usually one tablet once daily with or without food as advised.
Benefits: Improves glycemic control with low hypoglycemia risk and potential weight reduction.
How it Works: Empagliflozin (SGLT2 inhibitor) increases urinary glucose excretion, while linagliptin (DPP‑4 inhibitor) enhances incretin‑mediated insulin secretion and suppresses glucagon.
Side Effects: Genital/urinary infections, increased urination, cough, and rare hypoglycemia (with other agents).
Safety Advice: Contraindicated in severe renal impairment; maintain hydration and monitor renal function.
Storage: Store below 25–30°C.
Usage Instructions: Usually one tablet once daily with or without food as advised.
Benefits: Improves glycemic control with low hypoglycemia risk and potential weight reduction.
How it Works: Empagliflozin (SGLT2 inhibitor) increases urinary glucose excretion, while linagliptin (DPP‑4 inhibitor) enhances incretin‑mediated insulin secretion and suppresses glucagon.
Side Effects: Genital/urinary infections, increased urination, cough, and rare hypoglycemia (with other agents).
Safety Advice: Contraindicated in severe renal impairment; maintain hydration and monitor renal function.
Storage: Store below 25–30°C.
₹194.07
MRP: ₹215.63
Save ₹21.56
(9%)
Inclusive of all taxes
Quantity
Fresh Stock
Guaranteed
Guaranteed
Secure & Hygienic
Packaging
Packaging
Verified & Trusted
Supplements
Supplements
Secure
Payment
Payment
About: Glempa L 25/5 is a dual‑agent antidiabetic for type 2 diabetes in adults.
Usage Instructions: Usually one tablet once daily with or without food as advised.
Benefits: Improves glycemic control with low hypoglycemia risk and potential weight reduction.
How it Works: Empagliflozin (SGLT2 inhibitor) increases urinary glucose excretion, while linagliptin (DPP‑4 inhibitor) enhances incretin‑mediated insulin secretion and suppresses glucagon.
Side Effects: Genital/urinary infections, increased urination, cough, and rare hypoglycemia (with other agents).
Safety Advice: Contraindicated in severe renal impairment; maintain hydration and monitor renal function.
Storage: Store below 25–30°C.
Usage Instructions: Usually one tablet once daily with or without food as advised.
Benefits: Improves glycemic control with low hypoglycemia risk and potential weight reduction.
How it Works: Empagliflozin (SGLT2 inhibitor) increases urinary glucose excretion, while linagliptin (DPP‑4 inhibitor) enhances incretin‑mediated insulin secretion and suppresses glucagon.
Side Effects: Genital/urinary infections, increased urination, cough, and rare hypoglycemia (with other agents).
Safety Advice: Contraindicated in severe renal impairment; maintain hydration and monitor renal function.
Storage: Store below 25–30°C.